CAS: 25387-67-1; Sodium (S)-2-Hydroxy-2-(8-(Hydroxymethyl)-9-Oxo-9,11-Dihydroindolizino[1,2-B]Quinolin-7-yl)Butanoate

上下游产品

camptothecin

📜喜树碱 在 Sodium Hydroxide,水体系中,反应 2.0H,获得 20(S)-Camptothecin Sodium Salt
参考文献:Loading Of A Camptothecin Drug Into Colloidal Nanoparticles
标题:Loading Of A Camptothecin Drug Into Colloidal Nanoparticles
摘要:本发明涉及一种改进的制备含有羧酸形式的紫杉醇类药物的胶体纳米粒制剂的方法,以及一个试剂盒和一种药物组合物.

专利信息

专利号:US-5633260-A
优先权日:1994-04-19
标 题 :11,7 Substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
发明人：HAUSHEER FREDERICK H; HARIDAS KOCHAT
权利人:BIONUMERIK PHARMACEUTICALS INC
摘要:The novel compounds 11-hydroxy-7-ethyl camptothecin and 11-hydroxy-7-methoxy camptothecin (11,7-HECPT and 11,7-HMCPT) are active anticancer compounds which are poorly soluble in water. Because of their novelty, 11,7-HECPT and 11,7-HMCPT derivatives have not been directly administered by parenteral or oral routes to human subjects as an antitumor composition for the purpose of inhibiting the growth of cancer cells. The claimed compositions are useful as compared to the water soluble camptothecin derivatives, such as CPT-11, in clinical trials. The unpredictable interpatient variability in the metabolic production of an active metabolite from CPT-11 limits the utility of CPT-11. This invention overcomes these limitations by claiming novel pharmaceutically acceptable lactone stable formulations of 11,7-HECPT or 11,7-HMCPT, to directly administer to patients. The present invention also claims 11,7-HECPT and 11,7-HMCPT compositions, the synthesis of 11,7-HECPT or 11,7-HMCPT, the methods of formulation of 11,7-HECPT or 11,7 -HMCPT, and the methods of use of 11,7-HECPT or 11,7-HMCPT. Additionally, the claimed invention is directed to novel dosages, schedules, and routes of administration for both the 11,7-HECPT or 11,7-HMCPT formulations to humans with various forms of cancer. Other embodiments of this invention include isolation methods and methods of synthesis of certain camptothecin derivatives.

专利号:US-7687487-B2
优先权日:2007-04-19
标题 :Camptothecin-analog with a novel, “flippedâ€? lactone-stable, E-ring and methods for making and using same
发明人：HAUSHEER FREDERICK H
权利人:BIONUMERIK PHARMACEUTICALS INC
摘要:The present invention discloses: (i) a novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (ii) methods of synthesis of said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (iii) pharmaceutically-acceptable formulations comprising said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents; (iv) methods of administration of said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof; and (v) devices for the administration of said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more chemotherapeutic aents, to subjects in need thereof.

专利号:EP-2007386-B1
优先权日:2006-04-19
标题 :Camptothecin-analog with a novel, flipped lactone-stable, e-ring and methods for making and using same
发明人：HAUSHEER FREDERICK H
权利人:BIONUMERIK PHARMACEUTICALS INC
摘要:The present invention discloses: (i) a novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (ii) methods of synthesis of said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (iii) pharmaceutically-acceptable formulations comprising said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents; (iv) methods of administration of said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof; and (v) devices for the administration of said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more chemotherapeutic aents, to subjects in need thereof.